Leaderboards/Chimeric Antigen Receptor

Chimeric Antigen Receptor

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Xiaobing Wang
Unknown
765 cit.
2
Theresa Hunter
Unknown
582 cit.
3
David Steffin
Houston Methodist
567 cit.
4
Kim A. Reiss
University of Pennsylvania
516 cit.
5
Changsong Qi
Peking University
498 cit.
6
Michelle Monje
Howard Hughes Medical Institute
480 cit.
7
Dingpeng Zhang
Harvard University
411 cit.
8
Franck Morschhauser
Centre Hospitalier Universitaire de Lille
372 cit.
9
Nicholas A. Vitanza
Seattle Children's Hospital
360 cit.
10
Zhi Lin
University of California, San Francisco
339 cit.

Rising Stars Papers

1
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Cell|2024
254 cit.
2
In vivo CAR T cell generation to treat cancer and autoimmune disease
Science|2025
193 cit.
3
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Nature|2024
188 cit.
4
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Nature Medicine|2025
171 cit.
5
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Nature Medicine|2024
165 cit.
6
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature|2024
159 cit.
7
Transferrin receptor targeting chimeras for membrane protein degradation
Nature|2024
136 cit.
8
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Nature Medicine|2024
123 cit.
9
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Nature Medicine|2025
119 cit.
10
Multiscale photocatalytic proximity labeling reveals cell surface neighbors on and between cells
Science|2024
112 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Donald M. O’Rourke
Translational Therapeutics (United States)
678 cit.
2
Katayoun Rezvani
The University of Texas MD Anderson Cancer Center
651 cit.
3
Jennifer A. Doudna
QB3
504 cit.
4
Georg Schett
Università Cattolica del Sacro Cuore
441 cit.
5
Behnam Badie
City Of Hope National Medical Center
414 cit.
6
Li Tang
École Polytechnique Fédérale de Lausanne
381 cit.
7
Marco Ruella
Hospital of the University of Pennsylvania
372 cit.
8
Phillip K. Darcy
The University of Melbourne
309 cit.
9
Nizar J. Bahlis
University of Calgary
305 cit.
10
Christoph Scheiermann
University of Geneva
270 cit.

Emerging Leaders Papers

1
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Nature Medicine|2024
434 cit.
2
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
Nature Medicine|2024
317 cit.
3
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
New England Journal of Medicine|2024
881 cit.
4
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Nature Medicine|2024
276 cit.
5
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
Nature Biotechnology|2024
254 cit.
6
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Nature Medicine|2024
248 cit.
7
In vivo human T cell engineering with enveloped delivery vehicles
Nature Biotechnology|2024
214 cit.
8
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
Nature|2024
206 cit.
9
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Nature Medicine|2023
305 cit.
10
Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy
Cell|2024
180 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Carl H. June
Abramson Cancer Center
18.9k cit.
2
Crystal L. Mackall
National Institutes of Health
18.1k cit.
3
Michel Sadelain
Cornell University
16.4k cit.
4
Steven A. Rosenberg
National Institutes of Health
15.4k cit.
5
Stephan A. Grupp
University of Pennsylvania
14.2k cit.
6
Tanya Siddiqi
City Of Hope National Medical Center
6.9k cit.
7
David G. Maloney
Fred Hutch Cancer Center
6.3k cit.
8
Cameron J. Turtle
Fred Hutch Cancer Center
6.2k cit.
9
Malcolm K. Brenner
Methodist Hospital
5.9k cit.
10
William Y. Go
Kite (United States)
5.9k cit.

All-Time Leaders Papers

1
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
The Lancet|2014
2.9k cit.
2
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet|2020
2.3k cit.
3
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Journal of Clinical Investigation|2016
2.1k cit.
4
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine|2017
5.9k cit.
5
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
New England Journal of Medicine|2018
5.6k cit.
6
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
New England Journal of Medicine|2014
5.4k cit.
7
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Nature|2017
1.8k cit.
8
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Nature Medicine|2015
1.8k cit.
9
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Nature Medicine|2018
1.7k cit.
10
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Molecular Therapy|2010
2.5k cit.

All-Time Leaders Reagents

Coming soon

Indexing Chimeric Antigen Receptor Reagents

Citation data for reagents in this field is currently compiling.